COPD staat voor chronic obstructive pulmonary disease of chronisch obstructief longlijden. Het is een verzamelnaam voor chronische longziekten (chronische bronchitis en emfyseem) met als gemeenschappelijk kenmerk een over de jaren toenemende, grotendeels onomkeerbare beperking van de luchtstroom ter hoogte van de longen. Als lucht die in de longen zit moeilijk kan uitgeademd worden, krijg je een hyperinflatie van de longen (emfyseem), waarbij geleidelijk ademnood ontstaat.
Symptomen
Kortademigheid bij hevige inspanning, later ook bij milde inspanning en zelfs in rust
Hoesten en opgeven van fluimen
Gevolgen
COPD is een ziekte waarbij de luchtwegen als maar verder vernauwen. Tegelijk wordt het longweefsel rond de luchtwegen afgebroken. Dat is een traag, maar in principe onomkeerbaar proces.
Emfyseem
Longblaasjes worden vernietigd.
Longen verliezen hun elasticiteit, de longblaasjes scheuren en er ontstaan grote luchtholten.
Er is minder longweefsel om zuurstof op te nemen en koolstofdioxide af te geven.
Chronische bronchitis
Hardnekkige ontsteking van de luchtwegen met overproductie van slijm.
Het slijm belemmert de uitstroom van lucht tijdens de ademhaling.
Complicaties
De combinatie van een ongezonde levensstijl met ontsteking van de luchtwegen zorgt ervoor dat andere ziektes zich sneller ontwikkelen.
De voornaamste oorzaken van COPD:
Roken (90% van de gevallen)
Astma
Vervuilde lucht
Erfelijke factoren
Infecties van de luchtwegen
Therapie
Naast stoppen met roken, is een trainings- en revalidatieprogramma. Tijdens het revalidatieprogramma ligt de focus op inspanningstraining en krachtoefeningen. De longcapaciteit zelf verbetert niet noodzakelijk, maar de deelnemers van het programma kunnen met die verminderde longfunctie weer meer doen. Ze zijn minder kortademig en voelen zich veel beter. Dat effect is in tal van wetenschappelijke studies aangetoond.”
Het stofje carnosine zorgt ervoor dat je lichaam afvalstoffen afvoert. Bijvoorbeeld in de beenspieren, als je loopt of fietst. Door het stofje raak je niet te snel vermoeid of verzuurd en herstel je weer van het bewegen.
In onderzoek zag men dat mensen met COPD de helft minder van dit stofje in hun beenspieren hebben dan gezonde mensen. Daardoor zijn ze sneller vermoeid en hebben ze eerder last van ‘verzuring’’,. Uit eerder onderzoek weten we dat oudere mensen zonder COPD geholpen zijn met extra bèta-alanine. Ze kregen meer carnosine in de beenspieren en bij bewegen waren ze minder moe. We denken nu dat dat ook kan helpen bij mensen met COPD,
Fytotherapie?
Panax ginseng
Cannabis sativa
Pelargonium sidoides
Polygonum aviculare
Chronic obstructive pulmonary disease (COPD) as one of the health-threatening problems imposes many economic costs on health systems. Today, there is a greater tendency to use complementary and alternative therapies in the treatment of diseases. This study aimed to evaluate the efficacy of a Persian herbal formulation in patients with COPD.
Materials and methods: This randomized clinical trial was conducted on 76 patients with mild-severe COPD assigned to 2 groups (in each group n=38) for 8 weeks. The interventional group received Compound Honey Syrup (CHS), consisting of combination of honey and extracts of five medicinal plants (i.e., ginger, cinnamon, saffron, cardamom, and galangal) and the control group received a placebo. The COPD Assessment Test (CAT), St George's Respiratory Questionnaire (SGRQ), and lung function test were used before and after.
Results: Seventy-six patients, 88.6% male and 55.7% under 60 years of age, completed the course of treatment. At the end of the study, the overall score of the CAT questionnaire was significantly different between the first and fourth week (P=0.029). Meanwhile the findings of SGRQ questionnaire were significantly different between the interventional and control groups at other times (P=0.001). FEV1 and FEV1/FVC were found to be significantly different between two groups in weeks 4 and 8 (P <0.05). At the end of the study, no side effects of CHS were reported.
Conclusion: Based on the data presented herein, CHS could be effective as a complementary and safe drug in increasing the quality of life of with COPD.
Cannabinoids are a well-documented treatment modality for various immune and inflammatory diseases, including asthma, chronic obstructive pulmonary disease, Crohn's disease, arthritis, multiple sclerosis, and a range of neurodegenerative conditions. However, limited information is available regarding the therapeutic potential of cannabinoids in treating periodontal disease.
Objective: The objective of this study is to analyze the current evidence on the antibacterial and immunomodulatory effects of cannabis and its role in the healing and regeneration processes within periodontal tissues.
Results: This review discusses the potential role of cannabinoids in restoring periodontal tissue homeostasis.
Conclusions: The examination of the endocannabinoid system and the physiological effects of cannabinoids in the periodontium suggests that they possess immunomodulatory and antibacterial properties, which could potentially promote proper tissue healing and regeneration. https://pmc.ncbi.nlm.nih.gov/articles/PMC8542845/
De chronische longaandoening COPD gaat gepaard met een beperking van de kwaliteit van leven (Quality of Life, QoL) van de patiënt. De QoL is daarom een belangrijke parameter voor de evaluatie van een therapie in klinisch onderzoek. Bij een klinische studie naar het gebruik van het geregistreerde kruidenmiddel met het extract Pelargonium sidoides (EPs 7630) als aanvullende therapie bij COPD, is zowel naar de QoL als naar andere patiënt-gerapporteerde uitkomstmaten gekeken.
In het gerandomiseerde, dubbelblinde, placebogecontroleerde onderzoek werden 199 volwassenen met COPD in fase 2 of 3 onderverdeeld in twee groepen. Een groep onderging de standaardbehandeling volgens de Global Initiative for Chronic Obstructive Lung Disease (GOLD) en kreeg een placebo. De andere groep kreeg de GOLD aangevuld het pelargonium-extract EPs 7630. Gedurende 24 weken hielden de deelnemers de QoL en de volgende patiënt-gerapporteerde uitkomstmaten bij in een dagboek: de ernst van het hoesten, slijmvorming, pijn op de borst tijdens het hoesten en de duur dat iemand niet in staat was om te werken.
Na 24 weken waren in de pelargoniumgroep alle uitkomstmaten significant verbeterd ten opzichte van de groep met de placebobehandeling. Dit onderzoek toont aan dat pelargonium een goede aanvullende therapie is op de reguliere behandeling van COPD. Belangrijk te vermelden is ook dat het kruidenmiddel tijdens de gehele behandeltijd goed verdragen werd door de gebruikers.
Bron
Matthys, H., & Funk, P. (2018). Pelargonium sidoides preparation EPs 7630 in COPD: health-related quality-of-life and other patient-reported outcomes in adults receiving add-on therapy. Current Medical Research and Opinion, 34(7), 1245–1251.
Eur Respir J. 2006 Aug;28(2):330-8.
The aim of the current study was to systematically assess the effectiveness of herbal medicines in treating chronic obstructive pulmonary disease (COPD). Randomised clinical trials (RCTs) testing herbal medicines against any type of control intervention in patients with COPD and assessing clinically relevant outcomes were included. The selection of studies, data extraction and validation were performed independently by at least two reviewers. Methodological quality was evaluated using the Jadad score. Effect sizes and their 95% confidence intervals were calculated. Fourteen eligible RCTs, testing 14 different herbal medicines, were located. Herbal medicines were compared against placebo or no treatment in six trials. Significant intergroup differences for one or more outcome were reported for several herbal medicines including Panax ginseng and Salvia miltiorrhiza. In seven RCTs, which compared herbal medicines with other herbal medicines, the results were mixed. A single trial compared a herbal medicine (Hedera helix leaf extract) with a conventional treatment (ambroxol tablet) and reported no significant difference between groups. Due to the heterogeneity of the data, statistical pooling was not performed. The median methodological quality score was 2 out of a possible maximum 5. The effectiveness of herbal medicines for treating chronic obstructive pulmonary disease is not established beyond reasonable doubt. Currently, the evidence from randomised clinical trials is scarce and often methodologically weak. Considering the popularity of herbal medicine among chronic obstructive pulmonary disease patients, rigorously designed studies seem warranted.
Chronic obstructive pulmonary disease (COPD) is a group of conditions characterised by airflow obstruction 1. Chronic bronchitis (CB) and emphysema are two major conditions within this group. COPD is a public health concern worldwide, and the prevalence of this disease is increasing. According to the World Health Organization report in 1998, COPD was the sixth leading cause of death and the twelfth most common cause of morbidity worldwide. Both the direct and indirect economic costs of COPD to the society are substantial. In the USA, 16 million people have symptomatic COPD incurring estimated total economic costs for COPD-related morbidity and mortality of US$23.9 billion 2. In the UK, about 1.5 million patients suffer from COPD with a total annual cost to the National Health Service of ∼£491 million for direct costs only and £982 million including indirect costs 1.
There is no cure for COPD 3. Current conventional treatment is aimed at relieving symptoms, preventing recurrent exacerbations, preserving optimal lung function and enhancing the quality of life 4. Smoking cessation is the only therapeutic intervention shown to reduce disease progression 5. Although the conventional management of COPD has been improved since the 1990s, the progress is slow 6. Unsatisfactory treatment outcomes from conventional drugs, and adverse effects associated with several classes of drugs, such as steroids and theophylline, contribute substantially to the increasing popularity of complementary and alternative medicine (CAM) and, in particular, herbal medicine 7.
There is a long history of using herbal remedies to treat COPD, particularly in China, India and other Asian countries. Herbal expectorants, based on extracts from Hedera helix (ivy) or Thymus vulgaris (thyme) also enjoy considerable popularity in many European countries 8. Despite the popularity of herbal medicine, there has been no comprehensive systematic review of herbal medicines for treating COPD. The objective of the current review, therefore, was to systematically review the existing evidence on the effectiveness of herbal medicines for the treatment of COPD.
METHODS
All methods detailed below were according to a pre-defined, unpublished protocol.
Search strategy
Five electronic databases (AMED, MEDLINE, EMBASE, CINAHL and the Cochrane Library) were searched, from their respective inception to August 2005, without language restriction. Search terms were as follows: bronchitis, chronic obstructive pulmonary disease, COPD, acute exacerbation of chronic bronchitis (i.e. AECB), AECB, emphysema, herb*, botanic*, phyto*, Chinese medicine, plant extract*, plant preparation*, and individual common plant names and botanical names. Hand searches were performed in files and journals of the authors’ own library. Three manufacturers of relevant herbal remedies were contacted and asked to contribute further information, particularly unpublished data. The bibliographies of all included trials and other relevant reviews were searched to identify further potential trials.
Study selection
The clinical trials included in this review had to be of herbal preparations administered systemically for CB, emphysema or COPD, in which patients of either sex and of any age were randomly assigned to receive either herbal medicines or control treatments (i.e. placebo, no treatment, conventional therapy or other herbal medicines). Only trials assessing clinical outcomes (e.g. forced expiratory volume in one second (FEV1), global clinical assessment of effectiveness, symptom scores, health-related quality of life, exacerbation severity and frequency) were included. Trials including asthma patients were excluded.
Data extraction and methodological quality assessment
Titles and abstracts of identified articles were screened and full-text articles of potentially relevant trials were obtained. Articles in English and Chinese were read by R. Guo and articles in German by M.H. Pittler. These authors then discussed the articles and made decisions whether to include or exclude and, if needed, the third co-author (E. Ernst) was consulted. Data concerning the details of study design, participants, interventions, outcomes and adverse events were extracted from all included articles (R. Guo and M.H. Pittler). Missing data from one trial 9 were requested by contacting the author of the report. To date, a response has not been received.
The methodological quality of the included trials was assessed using the five-point scale developed by Jadad et al. 10. This was done either independently by two authors (R. Guo and M.H. Pittler) for randomised clinical trails (RCTs) published in English or by discussion of the same two authors for RCTs published in German or Chinese.
Data analysis
The included RCTs were categorised according to the type of control intervention and the following comparisons were made. 1) Herbal medicine versus placebo or no treatment; 2) herbal medicine versus conventional therapy; and 3) herbal medicine versus herbal medicine.
Due to the inadequate reporting, the overall results were unclear in some trials. The effect sizes and the 95% confidence intervals (CI) of primary outcomes of each of the studies were therefore calculated (R. Guo). Most trials reported FEV1 (in absolute volume or percentage of predicted value) as primary outcomes. Symptom scores and exacerbation frequency were also reported in some trials. Several Chinese trials reported the results of global assessment of effectiveness as the primary outcome measure. This was based on the “Chinese National criteria for the clinical diagnosis and treatment evaluation of chronic bronchitis” 11, where responses are categorised into four levels (excellent, good, moderate and no effect). The responder rates for the levels “good” and “excellent” were assessed. This was defined as the proportion of patients who met the following criteria: at least two of four symptoms (cough, sputum, dyspnoea and rale) disappeared and the other symptoms significantly improved, or at least three of the four symptoms significantly improved and the other symptom improved. Results for continuous data (FEV1, vital capacity (VC), symptom score, and exacerbation frequency and severity) were calculated as weighted mean differences and results for dichotomous data (responder rate) were calculated as risk ratio (the proportion of the responders in the test group divided by the proportion of responders in the control group). These results are presented in table 1⇓ and are summarised descriptively. Pooled results were not calculated because only single trials were located for each herbal intervention.
RESULTS
The current authors located a total of 529 potentially relevant titles and abstracts. Of these, 48 articles were obtained for detailed evaluation and 19 RCTs 9, 12–30 were subsequently identified for further analysis. No unpublished RCTs were located. Of the 19 RCTs identified for further analysis, five were excluded because they did not report clinically relevant outcomes 26, 27, did not test a herbal remedy 29, did not use a systemic route of administration 28, or included asthmatic patients 30. Figure 1⇓ provides a flowchart of all included and excluded trials.
Fourteen RCTs 9, 12–24 met all inclusion criteria and were assessed. The main characteristics of these studies are summarised in table 2⇓. They originate from four countries (China, n = 10; Germany, n = 2; Switzerland, n = 1; and Italy, n = 1) and were published between 1991 and 2004 in three languages (Chinese, n = 8; English, n = 4; and German, n = 2). A total of 1,359 subjects were randomised and 1,314 were analysed by the original investigators. Most of the trials studied herbal mixtures whereas four trials tested herbal monopreparations. Eleven studies included only adult subjects (three trials specified their subjects as senile), two included both children and adults, and one included children only. Patients were diagnosed as having COPD in five RCTs and CB in nine RCTs. In one RCT, patients were specified as being in remission whereas three other RCTs included patients in acute exacerbation.
The methodological quality of the trials was generally low with a median Jadad score of 2, ranging from 1 to 5 (tables 2⇓ and 3⇓). Of the 14 included RCTs, only three 9, 16, 24 described the methods for randomisation and five 9, 15, 17, 21, 22 mentioned double blinding, of which only one 9 described the method of blinding appropriately. Details of dropouts and withdrawals were described in only five trials 9, 15, 17, 21, 24. Only two trials 9, 15 were placebo controlled.
The 14 RCTs were categorised into three groups according to the type of control interventions. Detailed results are summarised in table 1⇓ and described below. Information on the preparations, such as manufactures and compositions, can be found in the Appendix.
Herbal medicines versus placebo or no treatment
The current authors located a total of six RCTs that compared herbal medicines with placebo or no treatment. Two RCTs 9, 15 compared herbal medicines with placebo and the other four 12–14, 16 compared herbal medicines with no treatment. In all of these RCTs, both the experimental and the control groups received the same adjunctive treatment regimen with conventional therapies (table 2⇓). Significant differences for pulmonary function, symptom score and/or responder rate were seen in several herbal remedies.
Panax ginseng
In one double-blind, placebo-controlled RCT 9, Panax ginseng (Ginsana®; Pharmaton SA, Basel, Switzerland) was found to be significantly superior to placebo in improving pulmonary functions, including FEV1. However, the available data were insufficient for effect size calculations. Another RCT 14 tested Shen Mai injection (Affiliated Pharmaceuticals of West China University, Chengdu, Sichuan, People’s Republic of China), which is a combination preparation containing three herbs including P. ginseng as the main ingredient (see Appendix), against no treatment. Significant improvements were found in all outcomes, including pulmonary function tests (FEV1, VC), global clinical assessment of effectiveness (responder rate) 11 and the Borg scale symptom score.
Salvia miltiorrhiza
One RCT 12 tested Salvia miltiorrhiza injection (Danshen injection; Sichuan Ya-an Pharmaceuticals, Ya-an, Sichuan, People’s Republic of China) against no treatment and found a significant improvement in FEV1. No significant difference in responder rate was found between treatment regiments.
Traditional Chinese herbal medicine
Two RCTs 13, 16 tested two traditional Chinese herbal medicine (TCHM) decoctions, Jinshui Liujin and Jiawei Yupingfeng (Appendix), against no treatment. In the Jiawei Yupingfeng trial 16, the responder rate in the TCHM group was found to be significantly higher compared with the no treatment group. In the Jinshui Liujin trial 13, the author reported significant improvement of all outcomes in both groups from baseline (p<0.05). Calculations of effect size and 95% CI showed no significant difference in any of the outcomes, including responder rate, FEV1 and VC, between groups.
Echinacea
One double-blind, placebo-controlled RCT 15 studied the effectiveness of Esberitox® N (Schaper and Brümmer GmbH & Co., Salzgitter, Germany), a liquid extract made from three herbs (Appendix), including Echinacea, as a supportive medication. Significant improvements in FEV1 were reported.
Herbal medicine versus conventional therapy
Only one RCT 17 was located that compared a herbal remedy with a conventional therapy. VC was assessed as the primary outcome. No statistically significant difference was seen between H. helix leaf extract (Prospan®) and ambroxol tablets (table 1⇓).
Herbal medicine versus herbal medicine
Seven RCTs 18–24 compared one herbal medicine with another (table 1⇓). One RCT 21 compared two forms of H. helix extract (Prospan® cough syrup and Prospan® herbal drops). No significant differences were found between groups in either FEV1 or VC. The other six RCTs tested one TCHM remedy against another. Five of these RCTs reported the results for the responder rate. Four trials 18, 19, 20, 23 showed positive results favouring test groups and one 22 showed no significant difference between groups. Only one trial 18 reported data for the pulmonary function test (FEV1), which showed no significant difference between groups. Two trials 24, 20 reported the results of symptom scores and both showed positive results favouring the test group. One trial 23 reported the assessment of exacerbation severity and frequency. The results suggested that both severity and frequency of exacerbation were significantly reduced in the test group compared with the control group.
Adverse events
Only five out of 14 trials included information on adverse events (AE). Two of these RCTs reported no AE in either group. The other studies reported mild-to-moderate AE with no further details (table 1⇓).
DISCUSSION
The present study has identified several herbal remedies with the potential to improve pulmonary function, to relieve symptoms or to reduce exacerbation severity and frequency in the treatment of COPD. Studies on herbal products containing P. ginseng, H. helix, S. miltiorrhiza and some TCHM decoctions generated encouraging results. However, interpretation and extrapolation of these results are difficult for a number of reasons.
First, insufficient data are currently available for any specific herbal remedy. Only one trial was identified for each of the tested herbal interventions and most of these trials were of small sample size and none reported formal sample size or power calculations.
Secondly, the overall methodological quality of the studies is low (table 3⇓). Blinding and randomisation are two essential features for minimising bias 31. However, in this review, only five out of 14 RCTs were double blinded. Part of the reason for the lack of blinding may be the difficulty in finding a credible placebo that is indistinguishable in colour, taste and smell, and also pharmacologically inert in the conditions under investigation. This may be particularly problematic for herbal decoctions. Similarly, four trials compared herbal medicines against “no treatment”, which does not account for placebo effects and is a source of bias. The method for randomisation was rarely described. In two RCTs 19, 20, there was a substantial difference between the numbers of patients in test and control groups. This could suggest that inappropriate methods of randomisation were used. These weaknesses, and the lack of descriptions of dropouts and withdrawals, contribute to the often low scores on the Jadad scale. The validity of some RCTs was further limited by failings to report the concealment of treatment allocation and details of statistical analysis, or inappropriate analyses.
Thirdly, seven RCTs compared a herbal medicine with another herbal medicine. Despite some positive results shown in these trials, interpretation is difficult due to the unknown effect of the control intervention.
Furthermore, quality control of the herbal extracts is important to ensure the reproducibility of the study. Of the 12 herbal preparations (excluding herbal decoctions) listed in the Appendix, data on extract standardisation are only available for one preparation. Details on the extract solvent were also only reported for one preparation.
Finally, the European Agency for the Evaluation of Medicinal Products recommended using both FEV1 and a measure of symptomatic benefit as a combined primary outcome, and states that the end-point for symptomatic benefit should be justified by referencing published data that support its validity 32. However, only one trial 14 used a referenced symptomatic benefit measure, in spite of the availability of a number of validated, well accepted and widely applied instruments, such as the St George's Respiratory Questionnaire 33 and Chronic Respiratory Questionnaire 34.
The increasing popularity and, particularly, the easy access to herbal remedies raises safety issues. The common assumption among consumers that herbal medicines are safe is dangerous. Herbal medicines might be linked to serious AE and herb–drug interaction may have serious clinical consequences 35. Several relevant herbs, such as Salvia milhiorrhiza, Glycyrrhiza uralensis, P. ginseng and Angelica sinensis were reported to interact with a range of conventional medicines 36–38. Unfortunately, in most of the included RCTs, AE were not monitored and herb–drug interactions were considered in none of the reports. The included studies involved a large number of individual herbs in various combinations (see Appendix). The AE and herb–drug interactions of most of these herbs and preparations are not well documented. Therefore, further studies on the safety of these remedies are required.
Limitations of the current review and, indeed, systematic reviews in general pertain to the potential incompleteness of the reviewed evidence. The distorting effects arising from publication bias and location bias are well documented 39–43. In the current review, 10 out of 14 included RCTs were published in China, a country which has been previously shown to produce large numbers of positive CAM studies 44. For the current study, databases were searched with a focus on the American and European literature and those which specialise in complementary medicine, and included hand-searches. There were no restrictions in terms of publication language. The current authors are, therefore, confident that their search strategy has located most of the published trials on the subject. However, whether all unpublished trials were identified remains uncertain. A further limitation of this review is (as pointed out previously) the paucity and limited quality of the primary data.
Conclusion
The effectiveness of herbal medicines for treating chronic obstructive disease is not established beyond reasonable doubt. Currently, the evidence from randomised clinical trials is scarce and often methodologically weak. Considering the popularity of herbal medicine among chronic obstructive pulmonary disease patients, rigorously designed studies seems to be warranted.
References
Chronic obstructive pulmonary disease – national clinical guideline on management of chronic obstructive pulmonary disease in adults in primary NICE. secondary care. Thorax 2004;59: Suppl. 1 1–232.FREE Full TextGoogle Scholar
Petty TL. Scope of the COPD problem in North America. Chest 2000;117: Suppl. 2 326S–331S.CrossRefPubMedWeb of ScienceGoogle Scholar
Johannsen J. Chronic obstructive pulmonary disease: current comprehensive care for emphysema and bronchitis. Nurse Pract 1994;19:59–67.PubMedGoogle Scholar
Siafakas N, Vermeire P, Pride P, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995;8:1398–1320.FREE Full TextGoogle Scholar
Barnes PJ. Chronic obstructive pulmonary disease * 12: new treatments for COPD. Thorax2003;58:803–808.FREE Full TextGoogle Scholar
Gross NJ. The GOLD standard for chronic obstructive pulmonary disease. Am J Respir Crit Care Med2001;163:1047–1048.PubMedWeb of ScienceGoogle Scholar
George J, Ioannides DLL, Santamaria NM, Kong DC, Stewart K. Use of complementary and alternative medicines by patients with chronic obstructive pulmonary disease. Med J Aust 2004;181:248–251.PubMedWeb of ScienceGoogle Scholar
Ziment I. Complementary and alternative medicine therapies for chronic obstructive pulmonary disease.Focus Alternat Complement Therap 2003;8:385–391.Google Scholar
Gross D, Shenkman Z, Bleiberg B, Dayan M, Gittelson M, Efrat R. Ginseng improves pulmonary functions and exercise capacity in patients with COPD. Monaldi Arch Chest Dis 2002;57:242–246.PubMedGoogle Scholar
Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1–12.CrossRefPubMedWeb of ScienceGoogle Scholar
Criteria for the clinical diagnosis. and treatment evaluation of chronic bronchitis – revised on the national conference of chronic bronchitis. Zhong Hua Jie He He Hu Xi Za Zhi 1980;3:61–62.Google Scholar
Wei ZM. Effects of injection Salviae miltiorrhizae on senile chronic asthmatic bronchitis patients.Zhongguo Zhong Xi Yi Jie He Za Zhi 1996;16:402–404.PubMedGoogle Scholar
Zhao CY, Shen YS, Meng H. Clinical and experimental study on Jinshui Liujun decoction in treating chronic bronchitis. Zhongguo Zhong Xi Yi Jie He Za Zhi 1997;17:264–266.PubMedGoogle Scholar
Fang Z, Jiang H, Wang L. Therapeutic effect of Shengmai injection on respiratory function in chronic obstructive pulmonary disease. Zhongguo Zhong Xi Yi Jie He Za Zhi 1998;18:520–522.PubMedGoogle Scholar
Hauke W, Köhler G, Henneicke Von Zepelin HH, Freudenstein J. Esberitox N as supportive therapy when providing standard antibiotic treatment in subjects with a severe bacterial infection acute exacerbation of chronic bronchitis: a multicentric, prospective, double-blind, placebo-controlled study.Chemotherapy 2002;48:259–266.CrossRefPubMedWeb of ScienceGoogle Scholar
Huang HQ, Lu F, Lu SY. Effect of Jiawei Yupingfeng powder on T-lymphocyte subsets in patients with senile chronic bronchitis in acute onset stage. Zhongguo Zhong Xi Yi Jie He Za Zhi 2004;24:109–111.PubMedGoogle Scholar
Meyer-Wegener J, Liebscher K, Hettich M, Kastner HG. Ivy versus ambroxol in the treatment of chronic bronchitis: a double-blind comparative study of clinical efficacy and tolerance of ivy dried leaf extract and ambroxol. Z Allg Med (Ind Med Gaz) 1993;69:61–66.Google Scholar
Cheng CL. Clinical and experimental research on chronic bronchitis treated with Ke Chuan Ping decoction. Zhong Xi Yi Jie He Za Zhi 1991;11:203–205.PubMedGoogle Scholar
Chen YQ, Zhang YP. Analysis of clinical effect and experimental study of 13 herbs anti-cough–dyspnea decoction in the treatment of chronic bronchitis. Zhongguo Zhong Xi YI Jie He Za Zhi 1993;13:27–29.PubMedGoogle Scholar
Xu XY, Liu QR, Chen J. Clinical observation of Qi deficiency syndrome in 72 patients with chronic obstructive pulmonary disease treated with Yiqi Mianyi granule. Zhongguo Zhong Xi YI Jie He Za Zhi1996;16:81–83.PubMedGoogle Scholar
Gulyas A, Repges R, Dethlefsen U. Therapy of chronic obstructive pulmonary diseases in children.Atemwegs Lungenkr 1997;23:291–294.Google Scholar
Mao B, Zhang RM, Li TQ. Clinical observation on effect of Kesuning granule in treating acute onset of chronic bronchitis. Zhongguo Zhong Xi Yi Jie He Za Zhi 2002;22:597–598.PubMedGoogle Scholar
Liu Y, Wang N, Wang N, Liu G, Yan H. Clinical observation in 31 cases of chronic bronchitis at remission stage treated with Bufei Keli. J Tradit Chin Med 2003;23:246–250.PubMedGoogle Scholar
Wu GZ, Liu HJ, Gao SF. Effect of Gubenhuataquyufa on plasma levels of nitric oxide and endothelin in chronic obstructive pulmonary disease patients during emission period: a randomized controlled study.Chin J Clin Rehab 2003;7:3352–3353.Google Scholar
Zhang JY. Clinical and experimental observations on chronic bronchitis treated with Pukeling. Zhonghua Jie He He Hu Xi Xi Ji Bing Za Zhi 1983;6:169–170.PubMedGoogle Scholar
Scaglione F. Immunomodulatory effects of Panax ginseng C.A. Meyer (G115) on alveolar macrophages from patients suffering with chronic bronchitis. Int J Immunother 1994;X:21–24.Google Scholar
Scaglione F, Weiser K, Alessandria M. Effects of the standardised ginseng extract G115® in patients with chronic bronchitis: a nonblinded, randomised, comparative pilot study. Clin Drug Invest 2001;21:41–45.CrossRefGoogle Scholar
Huo GR, Ma LQ, Huang CH. Clinical study on treatment of chronic bronchitis by tracheitis plaster.Zhongguo Zhong Xi Yi Jie He Za Zhi 2001;21:816–818.PubMedGoogle Scholar
Habermann W, Zimmermann K, Skarabis H, Kunze R, Rusch V. The effect of a bacterial immunostimulant (human Enterococcus faecalis bacteria) on the occurrence of relapse in patients with chronic bronchitis. Arzneimittelforschung 2001;51:931–937.PubMedGoogle Scholar
Mansfeld H-J. Hohre H, Repges R, Dethlefsen U. Klinische Studie: behandlung von Kindern mit chronisch obstrucktiven Atemwegserkrankungen mit Efeublättertrockenextrakt. [Clinical study: treatment for children with COPD using ivy extract.]. TW Pädiatrie 1997;10:155–157.Google Scholar
Resch K-L, Ernst E. : Research methodologies in complementary medicine: making sure it works. In: Ernst E, ed. Complementary Medicine: An Objective Appraisal. Oxford, Butterworth, 1996Google Scholar
EMEA. Points to consider on clinical investigation of medicinal products in the chronic treatment of patients with chronic obstructive pulmonary disease (COPD). CPMP/EWP/562/98. London, EMEA, 1999Google Scholar
Jones PW, Quirk FH, Baveystock CM, et al. A self complete measure for chronic airflow limitation: the St. Georges Respiratory Questionnaire. Am Rev Respir Dis 1992;145:1321–1327.CrossRefPubMedWeb of ScienceGoogle Scholar
Guyatt GH, Berman LB, Townsend M, et al. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987;42:773–778.Abstract/FREE Full TextGoogle Scholar
Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review.Drugs 2001;61:2163–2175.CrossRefPubMedWeb of ScienceGoogle Scholar
Fugh-Berman A. Herb–drug interactions. Lancet 2000;355:134–138.CrossRefPubMedWeb of ScienceGoogle Scholar
Izzo AA. Herb–drug interactions: an overview of the clinical evidence. Fundam Clin Pharmacol 2004;19:1–16.PubMedGoogle Scholar
Ioannides C. Pharmacokinetic interactions between herbal remedies and medicinal drugs. Xenobiotica2002;32:451–478.CrossRefPubMedWeb of ScienceGoogle Scholar
Dickersin K. The existence of publication bias and risk factors for its occurrence. JAMA1990;263:1385–1389.CrossRefPubMedWeb of ScienceGoogle Scholar
Egger M, Davey Smith G. Bias in location and selection of studies. BMJ 1998;316:61–66.FREE Full TextGoogle Scholar
Ernst E, Pittler M. Alternative therapy bias. Nature 1997;385:480PubMedGoogle Scholar
Pittler M, Abbot N, Harkness E, Ernst E. Location bias in controlled clinical trials of complementary/alternative therapies. J Clin Epidemiol 2000;53:485–489.CrossRefPubMedWeb of ScienceGoogle Scholar
Egger M, Zellweger-Zähner T, Schneider M, Junker C, Lengeler C, Antes G. Language bias in randomised controlled trials published in English and German. Lancet 1997;350:326–329.CrossRefPubMedWeb of ScienceGoogle Scholar
Vickers A, Goyal N, Harland R, Rees R. Do certain countries produce only positive results? A systematic review of controlled trials. Control Clin Trials 1998;19:159–166.CrossRefPubMedWeb of ScienceGoogle Scholar